JP2015514792A - ステロイド反応性皮膚病の治療方法 - Google Patents

ステロイド反応性皮膚病の治療方法 Download PDF

Info

Publication number
JP2015514792A
JP2015514792A JP2015507484A JP2015507484A JP2015514792A JP 2015514792 A JP2015514792 A JP 2015514792A JP 2015507484 A JP2015507484 A JP 2015507484A JP 2015507484 A JP2015507484 A JP 2015507484A JP 2015514792 A JP2015514792 A JP 2015514792A
Authority
JP
Japan
Prior art keywords
chloro
methyl
steroid
compound
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015507484A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514792A5 (https=
Inventor
パンカジュ、アガルワル
ビノッド、クマール
チン、シェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48143295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015514792(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2015514792A publication Critical patent/JP2015514792A/ja
Publication of JP2015514792A5 publication Critical patent/JP2015514792A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015507484A 2012-04-24 2013-04-22 ステロイド反応性皮膚病の治療方法 Pending JP2015514792A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261637390P 2012-04-24 2012-04-24
US61/637,390 2012-04-24
US201361782565P 2013-03-14 2013-03-14
US61/782,565 2013-03-14
PCT/EP2013/058249 WO2013160222A1 (en) 2012-04-24 2013-04-22 Treatment method for steroid responsive dermatoses

Publications (2)

Publication Number Publication Date
JP2015514792A true JP2015514792A (ja) 2015-05-21
JP2015514792A5 JP2015514792A5 (https=) 2016-06-16

Family

ID=48143295

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507484A Pending JP2015514792A (ja) 2012-04-24 2013-04-22 ステロイド反応性皮膚病の治療方法

Country Status (26)

Country Link
US (2) US20150087683A1 (https=)
EP (1) EP2841053A1 (https=)
JP (1) JP2015514792A (https=)
KR (1) KR20150010943A (https=)
CN (1) CN104302275A (https=)
AR (1) AR090795A1 (https=)
AU (1) AU2013254849B2 (https=)
BR (1) BR112014026706A2 (https=)
CA (1) CA2873751A1 (https=)
CL (1) CL2014002861A1 (https=)
CO (1) CO7111283A2 (https=)
CR (1) CR20140491A (https=)
DO (1) DOP2014000238A (https=)
EA (1) EA201491914A1 (https=)
HK (1) HK1201726A1 (https=)
IL (1) IL235159A0 (https=)
MX (1) MX2014012904A (https=)
NZ (1) NZ628394A (https=)
PE (1) PE20142356A1 (https=)
PH (1) PH12014502400A1 (https=)
SG (1) SG11201406409VA (https=)
TW (1) TW201347758A (https=)
UA (1) UA113875C2 (https=)
UY (1) UY34762A (https=)
WO (1) WO2013160222A1 (https=)
ZA (1) ZA201407345B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821299A (zh) * 2019-04-16 2020-10-27 天津合美医药科技有限公司 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518110A (ja) * 2007-02-07 2010-05-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性阻害剤
WO2010088331A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2011044414A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002734A1 (en) * 2004-07-01 2006-01-12 Unilever N.V. Moisture barrier
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
AU2006235314B2 (en) * 2005-04-12 2011-01-20 Merck Sharp & Dohme Corp. Inhibitors of Akt activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518110A (ja) * 2007-02-07 2010-05-27 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性阻害剤
WO2010088331A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2011044414A1 (en) * 2009-10-08 2011-04-14 Glaxosmithkline Llc Combination
WO2011146710A1 (en) * 2010-05-21 2011-11-24 Glaxosmithkline Llc Combination

Also Published As

Publication number Publication date
AR090795A1 (es) 2014-12-10
CL2014002861A1 (es) 2015-01-16
MX2014012904A (es) 2014-11-21
EA201491914A1 (ru) 2015-01-30
AU2013254849A1 (en) 2014-11-06
SG11201406409VA (en) 2014-11-27
US20160143885A1 (en) 2016-05-26
TW201347758A (zh) 2013-12-01
CN104302275A (zh) 2015-01-21
CR20140491A (es) 2014-12-22
ZA201407345B (en) 2015-11-25
UA113875C2 (uk) 2017-03-27
CO7111283A2 (es) 2014-11-10
AU2013254849B2 (en) 2016-05-26
US20150087683A1 (en) 2015-03-26
BR112014026706A2 (pt) 2017-06-27
HK1201726A1 (en) 2015-09-11
PH12014502400A1 (en) 2015-01-12
KR20150010943A (ko) 2015-01-29
CA2873751A1 (en) 2013-10-31
PE20142356A1 (es) 2015-01-30
EP2841053A1 (en) 2015-03-04
DOP2014000238A (es) 2014-12-15
IL235159A0 (en) 2014-12-31
WO2013160222A1 (en) 2013-10-31
UY34762A (es) 2013-11-29
NZ628394A (en) 2016-02-26

Similar Documents

Publication Publication Date Title
JP2024180450A (ja) ５－ｈｔ２ｂアゴニストの形成を阻害するための製剤およびその使用方法
JP2021502403A (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
US20240216369A1 (en) The use of a splicing modulator for a treatment slowing progression of huntington's disease
JP2008518891A (ja) Ｔリンパ球の増殖および／またはケラチノサイトの過剰増殖を特徴とする疾患、特にアトピー性皮膚炎および乾癬を処置するための、ピルリンドールの使用
EP3145513B1 (en) 3-(4-((4-(morpholinomethyl-benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione for the treatment of systemic lupus erythematosus
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
WO2021032213A1 (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
CN110652514A (zh) 第三代egfr抑制剂的制药用途
TW202131910A (zh) 使用mtorc1調節劑的治療方法
IL287665A (en) Combined treatments including apremilaste and tyk2 inhibitors
JP7703124B1 (ja) Ｓｅｒｄ投薬レジメンの組み合わせを使用してがんを治療する方法
JP2025510813A (ja) Ｔｙｋ２阻害剤及びその使用
KR20150120479A (ko) 니트라이트의 약제학적 제형 및 이의 용도
JP7640033B2 (ja) ピリド［１，２－ａ］ピリミジノン類似体の使用
WO2005034936A1 (en) Use of l-butylphthalide in the manufacture of medicaments for prevention and treatment of cerebral infarct
WO2014169710A1 (zh) 激酶抑制剂及治疗相关疾病的方法
CN105418599A (zh) 新盐及医药用途
JP2015514792A (ja) ステロイド反応性皮膚病の治療方法
AU2021383325B2 (en) Use of pridopidine and analogs for treating rett syndrome
CN101879169B (zh) 一种治疗血管相关疾病的复方制剂及其制备方法
JP2022501424A (ja) ４−アルキル−５−ヘテロアリール−３ｈ−１，２−ジチオール−３−チオンの回転異性体
CN116832023A (zh) 一种小分子化合物在制备防治或治疗脱发药物中的应用及其组合物
JP2024519342A (ja) 自己免疫性、同種免疫性、炎症性、及びミトコンドリア性の状態を治療するための組成物、ならびにその使用
CN102389425B (zh) 烟酸类衍生物在制备促卵泡发育和维护卵巢功能的药物中的应用
BRPI0713647A2 (pt) formulações farmacêuticas e composições de um antagonista seletivo cxcr2 ou cxcr1 e métodos para o uso do mesmo visando o tratamento de distúrbios inflamatórios

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20150626

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150717

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160418

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160418

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170328

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180213